Search

Your search keyword '"Fantoni, Jean-Christophe"' showing total 31 results
Start Over Author "Fantoni, Jean-Christophe" Publication Year Range Last 50 years
31 results on '"Fantoni, Jean-Christophe"'

1. Avelumab (A) as neoadjuvant therapy in patients (pts) with muscle-invasive urothelial carcinoma (MIUC): Survival data of AURA trial, Oncodistinct 004.

Author

Blanc, Jeremy, primary, Carnot, Aurélien, additional, Barthelemy, Philippe, additional, Casert, Vinciane, additional, Staudacher, Lionel, additional, Van den Brande, Jan, additional, Sautois, Brieuc, additional, Vanhaudenarde, Vincent, additional, Seront, Emmanuel, additional, Debien, Veronique, additional, Ameye, Lieveke, additional, Kotecki, Nuria, additional, Fantoni, Jean Christophe, additional, Tricard, Thibault, additional, Roumeguere, Thierry Andre, additional, Awada, Ahmad, additional, and Martinez Chanza, Nieves, additional

Published
2024
Full Text
View/download PDF

4. Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)

Author

Martinez Chanza, Nieves, Soukane, Louisa, Barthelemy, Philippe, Carnot, Aurélien, Gil, Thierry, Casert, Vinciane, Vanhaudenarde, Vincent, Sautois, Brieuc, Staudacher, Lionel, Van den Brande, Jan, Culine, Stephane, Seront, Emmanuel, Gizzi, Marco, Albisinni, Simone, Tricard, Thibault, Fantoni, Jean Christophe, Paesmans, Marianne, Caparica, Rafael, Roumeguere, Thierry, and Awada, Ahmad

Published
2021
Full Text
View/download PDF

6. Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial.

Author

Martinez Chanza, Nieves, primary, Carnot, Aurelien, additional, Barthélémy, Philippe, additional, Casert, Vinciane, additional, Staudacher, Lionel, additional, Van Den Brande, Jan, additional, Sautois, Brieuc, additional, Vanhaudenarde, Vincent, additional, Seront, Emmanuel, additional, Debien, Veronique, additional, Gil, Thierry, additional, Paesmans, Marianne, additional, Kotecki, Nuria, additional, Ignatiadis, Michail, additional, Albisinni, Simone, additional, Fantoni, Jean Christophe, additional, Tricard, Thibault, additional, Diamond, Romain, additional, Roumeguere, Thierry Andre, additional, and Awada, Ahmad, additional

Published
2022
Full Text
View/download PDF

7. Successful Reuse of Kidney Graft After Early Recurrence of Primary Focal and Segmental Glomerulosclerosis

Author

Hamroun, Aghilès, primary, Gibier, Jean-Baptiste, additional, Maanaoui, Mehdi, additional, Lionet, Arnaud, additional, Gnemmi, Viviane, additional, Bouyé, Sébastien, additional, Fantoni, Jean-Christophe, additional, Averland, Benoît, additional, Antoine, Corinne, additional, Lenain, Rémi, additional, Hazzan, Marc, additional, and Provôt, François, additional

Published
2021
Full Text
View/download PDF

8. Impact of positive vascular margins status after surgical resection of non-metastatic renal cell carcinoma with caval tumour thrombus: a propensity score multicentre study

Author

Vamour, Nicolas, primary, Gasmi, Anis, additional, Leroy, Xavier, additional, Puech, Philippe, additional, Koussa, Mohamed, additional, Villers, Arnauld, additional, Fantoni, Jean-Christophe, additional, Doumerc, Nicolas, additional, Bensalah, Karim, additional, Olivier, Jonathan, additional, and Khene, Zine‐Eddine, additional

Published
2021
Full Text
View/download PDF

16. Testicular natural killer T-cell lymphoma

Author

BALLEREAU, CHARLES, LEROY, XAVIER, MORSCHHAUSER, FRANCK, FANTONI, JEAN-CHRISTOPHE, LEMAITRE, LAURENT, VILLERS, ARNAULD, and BISERTE, JACQUES

Published
2005

22. Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas

Author

Classe, Marion, primary, Malouf, Gabriel G, additional, Su, Xiaoping, additional, Yao, Hui, additional, Thompson, Erika J, additional, Doss, Denaha J, additional, Grégoire, Valérie, additional, Lenobin, Julien, additional, Fantoni, Jean-Christophe, additional, Sudour-Bonnange, Hélène, additional, Khayat, David, additional, Aubert, Sébastien, additional, Tannir, Nizar M, additional, and Leroy, Xavier, additional

Published
2017
Full Text
View/download PDF

23. Les cancers de l’ouraque

Author

Peugniez, Charlotte, primary, Ghoneim, Tarek, additional, Leroy, Xavier, additional, Amela, Éric, additional, Fantoni, Jean-Christophe, additional, Culine, Stéphane, additional, Villers, Arnauld, additional, and Adenis, Antoine, additional

Published
2013
Full Text
View/download PDF

25. Cystocèles

Author

Mauroy, Brigitte, primary, Fantoni, Jean-Christophe, additional, and Lapray, Jean-François, additional

Published
2008
Full Text
View/download PDF

27. Prognostic value of combined p53 and survivin in pT1G3 urothelial carcinoma of the bladder.

Author

Samia Gonzalez, Sébastien Aubert, Olivier Kerdraon, Olivier Haddad, Jean-Christophe Fantoni, Jacques Biserte, Xavier Leroy, Gonzalez, Samia, Aubert, Sébastien, Kerdraon, Olivier, Haddad, Olivier, Fantoni, Jean-Christophe, Biserte, Jacques, and Leroy, Xavier

Subjects
BLADDER cancer, TUMORS, SURGICAL excision, PROGNOSIS, P53 antioncogene
Abstract

pT1G3 bladder tumors have a high tendency to recur and progress. We evaluated the prognostic values of the depth of submucosal invasion and immunostaining with survivin and p53 in 30 pT1G3 urothelial carcinomas at the first endoscopic resection. The depth of invasion was evaluated toward the muscularis mucosa and measured using a micrometer. Survivin and p53 immunostaining were performed using an automated immunostainer. Of the patients, 19 (63%) had tumor recurrence, 11 (37%) had tumor progression, 10 (33%) had metastatic spread, and 10 (33%) died of the disease. Infiltration of deep lamina propria (pT1b) and a micrometric measure of 1.5 mm or more were associated with an increased risk of tumor local and/or metastatic progression (P = .03 and P = .02, respectively). A combined high expression of survivin (

Published
2008
Full Text
View/download PDF

28. Active surveillance for non-muscle invasive bladder cancer.

Author

Marcq G, Hénon F, Ouzaid I, Fantoni JC, Hermieu JF, and Xylinas E

Abstract

Most of low grade (LG) bladder tumors will experience disease recurrence and very few of them (<2%) will experience disease progression. Therefore active surveillance (AS) for LG non-muscle invasive bladder cancer (NMIBC) has emerged. The goal of our study was to provide a literature review of AS for LG NMIBC including inclusion criteria, modalities and oncological outcomes. We conducted a systematic review (registered in PROSPERO: CRD42018102935) using MEDLINE and EMBASE between June 2018 and August 2018 with the following terms: LG, NMIBC, AS, urothelial neoplasm. Overall, 6 studies that reached our scope of review were included cumulating 403 patients with 2 prospective trials. Inclusion criteria were: recurrent LG (G1 and G2) Ta or T1 NMIBC, with a negative cytology, a low volume (<10 mm) and low number (<5) of tumors. Cystoscopy every 3 months during the first 2 years and every 6 months afterwards were required. AS dropout criteria were presence of tumor-related symptoms, a positive cytology, a modification of tumor morphology or size and patient's request. Pooled data showed an overall 65% reclassification rate where 15% of patients were reclassified based on grade and 10% on stage with a median follow-up of 32 months (IQR, 24-42 months). Only one study reported on progression to MIBC in 4 patients out of 186 (2%). Most of patients enrolled in an AS protocol for recurrent LG NMIBC will undergo a TURBT eventually. Many patients may be eligible to this therapeutic approach but current knowledge does not support its use in daily practice outside of a clinical trial., Competing Interests: Conflicts of Interest: The authors have no conflicts of interest to declare.

Published
2019
Full Text
View/download PDF

30. [Urachal cancers].

Author

Peugniez C, Ghoneim T, Leroy X, Amela E, Fantoni JC, Culine S, Villers A, and Adenis A

Subjects
Humans, Neoplasm Staging, Prognosis, Rare Diseases diagnosis, Rare Diseases pathology, Rare Diseases therapy, Urinary Bladder Neoplasms diagnosis, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms therapy
Abstract

Urachal cancer is a rare pathology (less than 1% among all bladder tumors) with a poor prognosis for all stages, because of clinical delay leading to a late diagnosis, difficult differential diagnosis with bladder cancer, and no consensus for the treatment, mostly about the chemotherapy for advanced stages, because there are no data from prospective studies. A surgical treatment can be performed for the localized stages, but there are no real guidelines for local relapses and metastatic progression treatment. Those cancers are not radio- or chemosensitive; nevertheless data from fundamental research are missing. As this pathology is really uncommon, there are no clinical studies with targeted therapies. The purpose of this review is to introduce the most important clinical and paraclinical features of those cancers, and the usual treatment performed.

Published
2013
Full Text
View/download PDF

31. [Primary neuroectodermal tumour of the kidney invading the wall of the inferior vena cava. Surgical strategy].

Author

Zini L, Nataf A, Fantoni JC, Villers A, Leroy X, Koussa M, Lemaitre L, and Biserte J

Subjects
Aged, Female, Humans, Kidney Neoplasms surgery, Neoplasm Invasiveness, Neuroectodermal Tumors, Primitive, Peripheral surgery, Vascular Neoplasms surgery, Kidney Neoplasms pathology, Neoplastic Cells, Circulating, Neuroectodermal Tumors, Primitive, Peripheral pathology, Vascular Neoplasms pathology, Vena Cava, Inferior
Abstract

Primary neuroectodermal tumours (PNET) are very aggressive malignant tumours, rapidly progressing to metastasis and death. They rarely involve the kidney, as only 23 cases have been described in the literature. Renal tumours, regardless of their histology, spread to the inferior vena cava (IVC) in 4% to 10% of cases. Invasion of the inferior vena cava wall by tumour thrombus is rare and, when it occurs, is often limited to the ostium of the renal vein. The authors report a case of primary neuroectodermal tumour of the kidney with thrombus in the inferior vena cava ascending to the right atrium (level IV), invading the wall of the IVC and associated with a non-infiltrating papillary urothelial tumour of the ureter. They describe the surgical management of this tumour and present a review of the literature.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results